Outsmarting Pandemic Viruses
As the COVID-19 pandemic persists, scientists around the world and at Georgia State are working tirelessly to outsmart new variants and plan for the next virus with pandemic potential.
The pandemic has produced a mental health crisis with effects that may reverberate for years — even decades — to come. At Georgia State, researchers are working to gain insights into the emotional toll and identify how people are finding hope even as the threats persist.
The research revealed a positive and significant association between COVID traumatic stress and PTSD symptoms, suggesting that the pandemic is a unique traumatic stressor.
The results highlight the potential for the virus to replicate and mutate in rodents, which often live in close proximity to humans.
In a study published online on Dec. 2 in Science, researchers in the Institute for Biomedical Sciences at Georgia State University report a new candidate that has potent antiviral activity against SARS-CoV-2 when administered orally once-daily.
The novel algorithm can help scientists explore how a virus is evolving in real time and inform decision-making by government leaders.
To better reach outpatients early after a COVID-19, infection, Gilead Sciences Inc. has partnered with researchers in Georgia State University’s Center for Translational Antiviral Research to test a modified version of remdesivir that can be taken orally.
New Georgia State University nursing graduate Kanika Coburn had reasons to be anxious about finishing her nursing education during the COVID-19 pandemic. However, thanks to the private 4 South Scholarship, money for school wasn’t a concern. The scholarship, established by an anonymous Georgia State alumna, led Coburn to her dream job as a nurse in the high-risk perinatal unit of Northside Hospital-Atlanta.
A new research center led by Richard Plemper in the Institute for Biomedical Sciences will develop critical antiviral drugs to meet the challenge of existing and newly evolving threats, such as coronaviruses.